Institute of Pharmaceutical Chemistry, Philipps University, Marbacher Weg 6, 35032 Marburg (Germany).
ChemMedChem. 2012 Nov;7(11):1965-73. doi: 10.1002/cmdc.201200292. Epub 2012 Aug 20.
During extracorporeal circulation, when blood comes in contact with artificial surfaces, patients receive a standard treatment with anticoagulants to avoid blood coagulation. Dialysis patients in particular are systemically treated with heparin up to four times a week, causing a high burden for the body. For potential anticoagulant modification of external materials, such as dialysis equipment, a series of highly potent thrombin inhibitors was developed. All inhibitors share the general formula arylsulfonyl-P3-Pro-4-amidinobenzylamide, where P3 is glycyl or a trifunctional amino acid residue in L-configuration. Among this series, several derivatives inhibit thrombin with Ki values of less than 1 nM. Specificity measurements revealed that this inhibitor type is highly specific for thrombin with negligible activity against related trypsin-like serine proteases. X-ray analysis of the most potent analogue in complex with thrombin demonstrated that the N-terminal arylsulfonyl group occupies the aryl binding site, whereas the P3 side chain is directed into the solvent and therefore is well suited for further coupling. Based on their in vitro profile, these inhibitors are suitable candidates for the development of hemocompatible materials with anticoagulant properties.
在体外循环过程中,当血液接触到人工表面时,患者会接受标准的抗凝治疗,以避免血液凝固。特别是透析患者每周要接受多达四次的肝素全身治疗,这给身体带来了很大的负担。为了对外部材料(如透析设备)进行潜在的抗凝修饰,研究人员开发了一系列强效的凝血酶抑制剂。所有抑制剂都具有相同的通式:芳基磺酰基-P3-脯氨酰-4-氨甲酰基苄酰胺,其中 P3 是甘氨酸或 L-构型的三功能氨基酸残基。在这个系列中,有几种衍生物对凝血酶的抑制 Ki 值低于 1 nM。特异性测量表明,这种抑制剂类型对凝血酶具有高度特异性,对相关的胰蛋白酶样丝氨酸蛋白酶几乎没有活性。与凝血酶形成复合物的最强类似物的 X 射线分析表明,N 端的芳基磺酰基占据了芳基结合位,而 P3 侧链则指向溶剂,因此非常适合进一步偶联。基于其体外特性,这些抑制剂是开发具有抗凝特性的血液相容性材料的合适候选物。